![Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology](https://jcp.bmj.com/content/jclinpath/61/9/1038/F1.large.jpg)
Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology
![Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis - ScienceDirect Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419314887-gr2.jpg)
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis - ScienceDirect
![Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-96170-5/MediaObjects/41598_2021_96170_Fig1_HTML.png)
Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports
![Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide](https://www.mdpi.com/cancers/cancers-14-02219/article_deploy/html/images/cancers-14-02219-g003.png)
Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
![Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies | Prostate Cancer and Prostatic Diseases Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41391-021-00456-8/MediaObjects/41391_2021_456_Fig1_HTML.png)
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies | Prostate Cancer and Prostatic Diseases
![Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy - Hartrampf - 2022 - The Prostate - Wiley Online Library Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy - Hartrampf - 2022 - The Prostate - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c5def381-c67b-46da-881e-29654ef69718/pros24414-fig-0003-m.jpg)
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy - Hartrampf - 2022 - The Prostate - Wiley Online Library
![Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging | SpringerLink Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12149-012-0601-8/MediaObjects/12149_2012_601_Fig2_HTML.gif)
Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging | SpringerLink
![Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/f88739ff-71c0-4bf0-935f-361ae3f12d77/gr1_lrg.jpg)
Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus
Clinical Case Discussions - Rising PSA 18 Months Post RP and Timing of Radiotherapy | Rising PSA 18 months post-RP & timing of radiotherapy. Ashley Ross, MD, PhD Northwestern University Feinberg School
![Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram](https://www.researchgate.net/publication/310585827/figure/fig4/AS:431670072483843@1479929573889/Tissue-PSA-distribution-across-the-prostate-gland-at-t-05-y-tumor-volume-evolution.png)